Adverum Biotechnologies (NASDAQ:ADVM) Research Coverage Star

HC Wainwright initiated coverage on shares of Adverum Biotechnologies (NASDAQ:ADVM – Free Report) in a report issued on Tuesday morning, Marketbeat reports. The brokerage issued a buy rating and a $30.00 target price on the biotechnology company’s stock. HC Wainwright also issued estimates for Adverum Biotechnologies’ Q1 2024 earnings at ($1.23) EPS, Q2 2024 earnings […]

Related Keywords

Monaco , James Paul Scopa , Adverum Biotechnologie , Newtyn Management , Citigroup Inc , Capital Management , Adverum Biotechnologies Inc , Adverum Biotechnologies Company Profile , Adverum Biotechnologies , Free Report , Moderate Buy , Get Free Report , Director James Paul Scopa , Asset Management , Apexium Financial , Adverum Biotechnologies Daily , Nasdaq Advm , Advm , Medical , Initiated Coverage , Hc Wainwright ,